Indivior stock steadies after Supernus merger deal highlights $2.2 billion revenue goal
Indivior stock is trading around $39 following the announcement of its merger with Supernus Pharmaceuticals, targeting a combined revenue of $2.2 billion. The merger aims to create a larger specialty pharmaceutical platform focused on central nervous system and addiction-treatment products, with potential workforce streamlining. Despite minor daily fluctuations, Indivior has shown positive year-to-date performance and its current stock price is well above its 52-week low.
Indivior stock edges higher as options activity and analyst targets point to further upside
Indivior stock is trading in the high-$30s, with recent options activity and analyst targets suggesting further upside potential. The stock closed at $39.43 on August 18, 2026, and analysts have an average target of $45.17, implying a 14.5% gain. This positive outlook is supported by recent bullish options flow and a consensus of six buy ratings and one hold rating from analysts.
Indivior Pharmaceuticals, Inc. (INDV) Options Chain
This article provides the options chain for Indivior Pharmaceuticals, Inc. (INDV), listing both call and put options with their respective strike prices, last trade dates, prices, and other relevant data. It includes current stock performance and related pharmaceutical tickers.
Indivior Plc (INDV) News, Articles, Events & Latest Updates
Indivior Plc (INDV) has been actively discussed in news concerning its proposed merger with Supernus Pharmaceuticals, Inc. The merger aims to create a CNS-focused biopharmaceutical leader with potential revenues of $2.2 billion. Various investor rights law firms are investigating the adequacy of the price and process of this proposed transaction for Indivior shareholders.
Is Indivior Pharmaceuticals Inc. (INDV) a Solid Growth Stock? 3 Reasons to Think "Yes"
Indivior Pharmaceuticals Inc. (INDV) is identified as a strong growth stock due to its favorable Zacks Growth Style Score and top Zacks Rank. The article highlights three key factors: strong projected earnings growth of 46.4%, robust year-over-year cash flow growth of 36%, and promising upward revisions in earnings estimates. These indicators suggest INDV is a potential outperformer for growth investors.
Indivior PLC (INDV) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Indivior PLC (INDV), highlighting its current earnings forecast score, average price target, and analyst ratings. Based on 5 analysts, the stock has a "Buy" trend with a target price of $49.000, suggesting a 27.37% upside. The report also details expected revenue and EPS for upcoming quarters.
Hennion & Walsh Asset Management Inc. Invests $14.78 Million in Indivior PLC $INDV
Hennion & Walsh Asset Management Inc. has acquired a new stake in Indivior PLC (NASDAQ:INDV) worth approximately $14.78 million, representing 0.30% of the company. Institutional investors collectively own 60.33% of Indivior, which currently holds a "Moderate Buy" consensus rating with an average price target of $45.17. However, the company faces uncertainty due to a law firm's investigation into its proposed Supernus acquisition, raising concerns about potential share dilution.
Assenagon Asset Management S.A. Buys Shares of 1,540,928 Indivior PLC $INDV
Assenagon Asset Management S.A. has acquired 1,540,928 shares of Indivior PLC (NASDAQ:INDV), representing a 1.26% stake worth approximately $63.2 million. Institutional investors now collectively own 60.33% of the company. Indivior recently reported strong quarterly earnings of $5.75 per share, surpassing full-year analyst expectations, while the stock trades near its 50-day moving average and analysts maintain a "Moderate Buy" rating.
Indivior PLC (INDV) Stock News Today
This page provides news and analysis for Indivior PLC (INDV) stock. It includes current stock price, market capitalization, P/E ratio, and states that more news will be available soon. The platform, TradingKey, offers general information and does not provide financial advice.
Earnings call transcript: Supernus and Indivior post Q2 2026 beat on merger news
Supernus Pharmaceuticals and Indivior Pharmaceuticals announced a Q2 2026 earnings beat and their planned all-stock merger. The combined entity will focus on central nervous system drugs, aiming for $2.2 billion in annual revenue and $125 million in annual cost savings. The merger, expected to close in Q4 2026, will create a CNS leader with a diversified portfolio and enhanced financial flexibility.
HC Wainwright Predicts Indivior's Q3 Earnings (NASDAQ:INDV)
HC Wainwright has increased its Q3 2026 EPS estimates for Indivior (NASDAQ:INDV) to $0.93 from $0.78, with forecasts rising through FY2030. Despite a recent price target cut by Barclays, analyst sentiment remains a "Moderate Buy" with an average target of $45.17. Indivior's shares opened up 6.1% at $38.73, and institutional investors hold a significant portion of the stock, while recent insider transactions show both purchases and sales.
Indivior Q2 Earnings Call Highlights
Indivior and Supernus Pharmaceuticals announced an all-stock merger of equals, creating a CNS-focused biopharmaceutical company with an estimated $2.2 billion in pro forma trailing-12-month net revenue. The combined entity will retain the Supernus name and be led by Supernus CEO Jack Khattar. The merger is expected to generate $125 million in annual cost synergies and aims to leverage a diversified portfolio, with Indivior's SUBLOCADE being the largest product contributor.
Indivior Pharmaceuticals, Inc. (INDV) Stock Analysis: Analyst Consensus Points to 36% Upside Potential
Indivior Pharmaceuticals, Inc. (INDV) is positioned as a key player in opioid dependence treatment, with strong analyst consensus pointing to a 36% upside potential. The company's focus on buprenorphine-based treatments, robust revenue growth of 19.20%, and a product pipeline including SUBLOCADE and SUBOXONE contribute to its attractive outlook. Despite short-term overbought signals, its solid financial foundation and positive market sentiment make it a compelling long-term investment in the healthcare sector.
Indivior Pharmaceuticals, Inc. Quarterly Earnings Report
Indivior Pharmaceuticals, Inc. (INDV) has released its Q2 2026 earnings report, detailing an increase in net revenue driven by strong U.S. sales of SUBLOCADE. The company also announced a proposed all-stock merger with Supernus Pharmaceuticals, Inc., which includes a conditional $1 billion special cash dividend to Indivior shareholders. This report also outlines ongoing litigation, including dental allegations related to SUBOXONE Film and civil opioid lawsuits, alongside a share repurchase program.
$1.8bn merger unites Supernus and Indivior in CNS therapeutics play
Supernus Pharmaceuticals and Indivior Pharmaceutical are merging in an all-stock transaction valued at $1.8 billion, aiming to create a stronger entity in the CNS therapeutics space. The combined company, to be named Supernus, Inc., will leverage commercial and pipeline synergies across neurological and psychiatric disorders, including Parkinson's disease and addiction treatments. The merger is expected to generate $125 million in annual cost synergies by 2027 and achieve positive adjusted EBITDA in its first full year.
indivior plc. Positive Earnings Pre-Announcements
Indivior plc. (INDV.L, INDV) has pre-announced positive earnings, revising its fiscal year 2026 revenue guidance upwards from an estimated range of $1.215 - $1.285 Billion to $1.295 - $1.365 Billion. This announcement is part of a broader calendar of earnings pre-announcements available through RTTNews. The article also includes a "News for indivior plc." section, listing several recent positive financial and strategic updates for the company.
indivior plc. Positive Earnings Pre-Announcements
Indivior plc. has pre-announced positive earnings, with estimated revenue for FY26 now ranging from $1.295 - $1.365 Billion, an increase from the previous range of $1.215 - $1.285 Billion. This update was reported on August 3, 2026, by RTTNews.
Supernus, Indivior merge to beef up brain drug portfolio
Brain drug developers Supernus and Indivior have announced a merger aimed at combining their portfolios of neurological drugs. The new entity, to be called Supernus, will have a combined revenue of $2 billion (2025 figures) and aims to achieve annual cost reductions of $125 million. This strategic move is expected to create a diversified portfolio with projected sales of $2.2 billion and earnings of $888 million, with growth anticipated into the 2030s.
Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
Indivior Pharmaceuticals Inc. announced strong financial results for the second quarter of 2026, with total net revenue up 14% year-over-year to $343 million and SUBLOCADE net revenue increasing by 21% to $253 million. The company has raised its full-year 2026 financial guidance, now expecting total SUBLOCADE net revenue growth of 20% and adjusted EBITDA growth of 68% year-over-year at the midpoint. Indivior also repurchased approximately 4.7 million shares for $175 million in Q2 2026 and announced a definitive agreement to merge with Supernus Pharmaceuticals, Inc.
Indivior Q2 Earnings Call Highlights
Indivior and Supernus Pharmaceuticals announced an all-stock merger of equals, creating a CNS-focused biopharmaceutical company with approximately $2.2 billion in pro forma annual revenue. The combined entity, retaining the Supernus name and led by Supernus CEO Jack Khattar, is expected to achieve $125 million in annual cost synergies within the first year. Indivior shareholders will receive a $1 billion aggregate dividend before the deal closes, with SUBLOCADE projected to be the largest revenue contributor for the new company.
Indivior stock soars 9% on strong earnings beat and raised guidance
Indivior Pharmaceuticals Inc. (NASDAQ:INDV) saw its stock rise by 9.22% after reporting strong second-quarter results that exceeded analyst expectations. The company also raised its full-year 2026 revenue and adjusted EBITDA guidance, driven by record SUBLOCADE net revenue. This performance reflects strong operational execution and increased sales volume for its key product.
Supernus and Indivior Combine to Build $2.2B CNS Biopharmaceutical Company
Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in an all-stock deal to form a $2.2 billion central nervous system (CNS) biopharmaceutical company. The combined entity, operating as Supernus, Inc., will integrate Indivior's opioid use disorder franchise, centered on SUBLOCADE, with Supernus's diverse neurology and psychiatry portfolio. This strategic merger aims to leverage complementary franchises and a specialized salesforce to address co-occurring conditions in patients and fund further growth initiatives.
Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
Indivior Pharmaceuticals reported strong second-quarter 2026 financial results, with total net revenue up 14% year-over-year to $343 million and SUBLOCADE net revenue increasing by 21% to $253 million. The company has raised its full-year 2026 guidance, now expecting total SUBLOCADE net revenue growth of 20% and adjusted EBITDA growth of 68%. Indivior also announced a proposed all-stock merger with Supernus Pharmaceuticals, Inc. to create a diversified CNS-focused biopharmaceutical company.
Form 4 Indivior PLC For: 3 August By Investing.com
This article announces the filing of Form 4 for Indivior PLC on August 3rd. It appears to be a very brief notification from Investing.com, typical of automated financial news updates regarding regulatory filings. The content primarily consists of navigation, advertisements, and market data rather than detailed article text.
Indivior PLC (NASDAQ:INDV) Given Average Recommendation of "Moderate Buy" by Brokerages
Indivior PLC (NASDAQ:INDV) has received an average "Moderate Buy" recommendation from seven brokerages, with an average 12-month price target of $43.67. The company's stock opened at $40.01, and analysts project full-year earnings of $4.05 per share. Recent insider transactions show executives selling shares under pre-arranged trading plans, while institutional investors have increased their stakes in the company.
Indivior Q2 2026 slides: SUBLOCADE drives 111% EBITDA surge
Indivior PLC reported strong Q2 2026 financial results, with adjusted EBITDA surging 111% driven by its opioid use disorder treatment, SUBLOCADE. Despite exceeding analyst expectations, the company's stock experienced a slight decline, likely due to investor caution regarding its proposed merger with Supernus Pharmaceuticals. Indivior also raised its full-year 2026 financial guidance, anticipating significant growth in revenue and adjusted EBITDA.
Indivior Q2 Earnings Call Highlights
Indivior and Supernus Pharmaceuticals announced an all-stock merger of equals, expected to close in Q4 2026, creating a CNS-focused biopharmaceutical company with approximately $2.2 billion in pro forma trailing-12-month net revenue. The combined entity will retain the Supernus name and be led by Supernus CEO Jack Khattar. The merger aims to leverage complementary businesses across addiction, ADHD, depression, and Parkinson’s disease, with anticipated annual cost synergies of $125 million within the first year.
Indivior PLC Lobbyists, 2023
This article from OpenSecrets details Indivior PLC's lobbying activities and lobbyists for the year 2023. It identifies 19 named lobbyists, with 15 (78.9%) having a "revolving door" background, meaning prior federal government employment. The report breaks down lobbyists by hiring firm, including Williams & Jensen and Crossroads Strategies, and provides a sortable roster of all individuals involved.
Indivior PLC (INDV) Financial Health: Profitability & Balance Sheet Analysis
Indivior PLC (INDV) has a current financial score of 7.94, ranking 87th out of 155 in the Pharmaceuticals industry, indicating a weak financial status despite high operating efficiency. The company reported a 19.17% year-over-year increase in quarterly revenue to $317.00 million and a 93.48% increase in net profit. However, specific data for Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns were not disclosed yet.
Indivior Number of Employees 2026 | Employee Count & Headcount Data
Indivior Ltd. has an estimated 1,015 employees worldwide as of March 2026, marking a 25.4% decline in headcount since 2023. The Pharmaceuticals company, headquartered in Bon Air, Virginia, is actively hiring with 50 job postings in 2026, though this represents a 5.8% decline from 2025. The company's workforce is primarily concentrated in the United States, and overall employee sentiment is reported as negative and declining.
Indivior PLC (INDV) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Indivior PLC (INDV), highlighting its strong valuation score of 9.73, which ranks it highly within the Pharmaceuticals industry. It details the company's current P/E ratio, its market capitalization, and stock performance, while noting that data for P/B, P/S, and P/CF ratios are not yet disclosed. The analysis aims to offer insights for investors considering INDV.
INDV|Indivior PLC|Price:40.970|Chg%:+0.940
This article provides a comprehensive stock analysis of Indivior PLC (INDV) by TradingKey, highlighting its strong fundamentals, high growth potential, and "fairly valued" status within the Pharmaceuticals industry. The analysis details Indivior's score, key insights, and an overview of its product portfolio for substance-use disorders, noting a high institutional ownership and indicating an expected upward trend for the stock in the medium term. It also includes an analyst consensus of "Buy" with a target price of $49.17.
Indivior PLC (INDV) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Indivior PLC (INDV), highlighting its current risk score of 6.43, ranking 53 out of 155 in the Pharmaceuticals industry. The company's beta of 1.18 suggests it tends to outperform during market uptrends but underperform during downtrends. The assessment also details various volatility, return, and liquidity metrics over different periods.
Indivior PLC (INDV) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Indivior PLC (INDV), highlighting its current earnings forecast score, analyst ratings, and price targets. It details expected revenue and EPS for upcoming quarters and compares Indivior's analyst coverage with peers in the Pharmaceuticals industry.
Indivior PLC (INDV) Balance Sheet
This article provides a detailed balance sheet for Indivior PLC (INDV), offering quarterly and annual financial data spanning several years. It allows users to analyze the company's financial health, including assets, liabilities, and shareholders' equity, along with key financial ratios. The data presented covers various financial components such as cash, receivables, inventory, non-current assets, and different types of liabilities.
Indivior PLC Lobbying Profile, 2026
This OpenSecrets profile details Indivior PLC's lobbying activities for 2026. The company, operating in the Pharmaceuticals/Health Products industry, spent $250,000 on direct lobbying efforts between January 1 and March 31, 2026. This profile includes sections on hired firms, lobbyists, issues, agencies, and bills related to Indivior's lobbying.
Indivior PLC (INDV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a brief overview of Indivior PLC's (INDV) revenue breakdown, focusing on its regional contribution. As of a past report, the United States accounted for 85.03% of the company's revenue, while the Rest of World contributed 14.97%. The document indicates that detailed segment-specific and more recent financial data have not yet been disclosed.
Indivior PLC (INDV) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Indivior PLC's (INDV) dividend history and stock splits, noting that no dividend data is available for the past five years. It also includes current stock performance metrics such as market capitalization and P/E ratio, and basic contact information for content collaboration and user feedback.
Indivior (INDV) Short Interest & Short Float | Updated Jul 2026
Indivior (INDV) currently has a short interest of 11.28 million shares, representing 9.32% of its public float, as of July 15, 2026. This indicates a 4.61% increase in short interest since the previous report, with a short interest ratio of 7.6 days to cover. The article provides detailed historical short interest data for INDV, along with FAQs about short interest metrics and comparisons to competitors in the pharmaceutical products industry.
Indivior to Report Second Quarter 2026 Financial Results and Host Webcast
Indivior Pharmaceuticals Inc. announced it will report its second-quarter 2026 financial results on Tuesday, August 4, 2026, at 7:00 a.m. U.S. EDT. Following the release, the leadership team will host a live webcast presentation at 8:00 a.m. U.S. EDT. The webcast and materials will be accessible via the "Investors" section of the company's website.
Indivior to Report Second Quarter 2026 Financial Results and Host Webcast
Indivior Pharmaceuticals Inc. announced it will release its second-quarter 2026 financial results on Tuesday, August 4, 2026, at 7:00 a.m. U.S. EDT. Following the release, CEO Joe Ciaffoni and other leadership team members will host a live webcast presentation at 8:00 a.m. U.S. EDT to discuss the results. Access to the webcast and presentation materials will be available on the company's website.
Indivior (INDV) Q1 2026 earnings summary
Indivior (INDV) reported strong Q1 2026 earnings, with net revenue increasing 19% year-over-year to $317 million, largely due to a 32–33% rise in SUBLOCADE sales. Adjusted EBITDA saw a significant jump of 112% to $164 million, and net income almost doubled to $89 million. The company also raised its full-year 2026 guidance for both revenue and adjusted EBITDA, reflecting positive outlook and robust SUBLOCADE performance.
Indivior stock trades steady as opioid treatment specialist rebuilds after 2024 setback
Indivior PLC is rebuilding investor confidence after a challenging 2024 marked by significant litigation costs that led to a net loss of $140 million, despite stable revenue and improved adjusted operating profit. The company is focusing on strengthening its balance sheet through debt reduction and investing in its pipeline of addiction treatments beyond its flagship product, Suboxone Film, to ensure long-term growth and stability. Investors are watching for consistency in financial performance and further resolution of legal issues to gauge the success of its strategic pivot and the fading of its legal overhang.
Indivior stock holds a recovery path as opioid treatment demand supports revenue
Indivior PLC's stock is showing signs of recovery, driven by strong demand for its opioid use disorder treatments and its ability to manage past legal settlements. The company's revenue growth, profitability metrics, and market capitalization are key indicators investors use to evaluate its balance of opportunities and risks. Indivior's focus on buprenorphine-based products, new product development, and clear guidance are crucial factors influencing its market valuation.
Indivior stock trades steadily as recent earnings and guidance frame addiction-treatment strategy
Indivior stock is trading steadily despite ongoing scrutiny, reflecting strong earnings, improved margins, and reduced legal provisions. The company, focused on addiction treatment, reported annual revenue above $1 billion in fiscal 2025 and improved operating cash flow. Investors are closely watching prescription volumes for key products and the progress of its pipeline, while the stock's mid-cap valuation balances growth opportunities with residual risks.
Indivior stock trades steady as revenue grows and opioid treatment portfolio expands
Indivior PLC, a specialty pharmaceutical company focused on opioid use disorder and addiction treatments, shows steady stock performance driven by growing revenues and resilient margins. The company's financial health is supported by its buprenorphine-based products, diversification into extended-release injectable formulations, and disciplined cost management, despite historical legal challenges and a competitive market. Investors are keenly focused on Indivior's ongoing margin performance, the management of legal and regulatory risks, and the progress of its development pipeline as key drivers for long-term shareholder value.
Indivior stock trades steady as opioid treatment specialist focuses on growth after recent earnings
Indivior's stock performance is influenced by the balance between its growing opioid use disorder treatment sales and ongoing legal settlement costs. The company's recent earnings show strong revenue growth driven by its flagship opioid use disorder therapies, with profitability metrics indicating underlying operational strength despite the impact of non-recurring legal charges. Investors are focused on Indivior's ability to manage its financial obligations, invest in its R&D pipeline, and navigate the complex regulatory environment.
Indivior stock holds steady as addiction-treatment strategy stays in focus
Indivior stock reflects the company's focus on addiction therapies, particularly opioid use disorder, positioning it within long-term healthcare trends. The company's strategy involves expanding treatment options, operating within a heavily regulated environment, and facing competition in a specialized niche. Its long-term approach includes R&D to improve existing treatments and explore new formulations, with its market position influenced by societal trends and regulatory developments.
Indivior (INDV) Q4 2025 earnings summary
Indivior (INDV) reported record SUBLOCADE net revenue of $856M in 2025, up 13% year-over-year, contributing to total net revenue of $1.24B. Adjusted EBITDA grew 20% to $428M, with a significant margin improvement. The company also resolved a DOJ matter for $295M and authorized a $400M share repurchase program, while providing optimistic guidance for 2026 with expected total net revenue between $1.125B and $1.195B.
Indivior (INDV) Morgan Stanley 23rd Annual Global Healthcare Conference Summary
Indivior presented at the Morgan Stanley 23rd Annual Global Healthcare Conference, focusing on its "Action Agenda" with SUBLOCADE as the main growth driver. The company detailed efforts in organizational simplification, cost reduction, and improving commercial execution, especially in the U.S. Indivior also provided financial guidance, expressing confidence in meeting 2025 targets and outlining plans for capital allocation and market strategy for SUBLOCADE amidst competition.
